Summary: Investigators in the United States (US) are currently recruiting approximately 200 people with all types of MS who are experiencing central neuropathic pain for a clinical research study to determine if the investigational use of the oral study drug, duloxetine hydrochloride, versus placebo, is safe and effective at reducing neuropathic pain associated with MS. The study is sponsored by Eli Lilly and Company.
Rationale: Approximately 55% of people with MS experience pain. There are two types of chronic pain caused by MS – neuropathic pain (caused by nerve damage) and non-neuropathic pain (caused by muscle spasms or contractions). Neuropathic pain is often described as burning, stabbing, and shooting pain in the legs and arms; and numbness, tingling, prickly, or “pins and needles” sensations. The purpose of this study is to evaluate the investigational use of duloxetine hydrochloride to determine if it reduces neuropathic pain experienced by those with MS. The drug being studied belongs to the group of medications known as selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). The study drug has not been approved for the treatment of MS or MS pain.
Click here to continue reading from the MS Society website and to learn where you can apply for this research study============================================